Skip to Content

Genetically Engineered Immune Cells Are Showing Promise in Fighting HIV

January 3, 2018

CAR-T therapy, a treatment that reprograms DNA of immune cells so they attack disease, has been shown to suppress or even eradicate HIV in lab monkeys.

How it works: As Stat explains, the engineered immune cells seek out and bind to the virus and are also themselves immune to HIV infection, allowing them to keep working.

But: The technique, published in PLoS One, was only tested in lab dishes and two animals. It’s also unclear how long the benefits may last. Given that CAR-T therapies have historically been very expensive, it would likely need to be an out-and-out cure to prove successful.

Backstory: We’ve explained how CAR-T shows huge promise in treating cancer, and many firms are already investing heavily in the hope that the technique will find broader application. That hope, this news suggests, may prove to be founded.

Deep Dive


The first babies conceived with a sperm-injecting robot have been born

Meet the startups trying to engineer a desktop fertility machine.

Doctors have performed brain surgery on a fetus in one of the first operations of its kind

A baby girl who developed a life-threatening brain condition was successfully treated before she was born—and is now a healthy seven-week-old.

A brain implant changed her life. Then it was removed against her will.

Her case highlights why we need to enshrine neuro rights in law.

The FDA just approved rub-on gene therapy that helps “butterfly” children

Biotech companies are getting creative with how they deliver DNA fixes into people's bodies.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at with a list of newsletters you’d like to receive.